Studies from our group have added to these data by demonstrating tumor-expressing CD38 is significantly upregulated in Kras/p53 mutant lung tumors during treatment with anti-PD-L1 or –PD1 antibodies, and this upregulation promotes treatment resistance [24]. The gene discussed is CD38; the disease is neoplasm.